The introduction of direct-acting anti-virals has increased sustained virological response rates in chronic hepatitis C genotype 1 infection.
At present, data on long-term durability of viral eradication after successful triple therapy are lacking.
Dr Rutter and colleagues from Austria assessed the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals.
The team evaluated patients who participated in randomized, controlled trials or an extended access program of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral were followed after achieving sustained virological response.
|2 cases of late relapses were observed|
|Alimentary Pharmacology & Therapeutics|
The median follow-up after the patients was 21 months.
The doctors followed 103 patients with chronic hepatitis C genotype 1 infection achieving a sustained virological response triple therapy.
The team observed 2 cases of late relapses.
The research team noted that 1 patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment.
The relapses occurred 8 and 12 months after cessation of anti-viral treatment.
The research team reported that cloning sequencing revealed identical sequence in both patients.
Resistance analysis revealed no presence of viral resistance.
Dr Rutter's team concluded, "Like the sustained virological response after peginterferon-α2/ribavirin combination treatment, Hepatitis C virus eradication after triple therapy remains durable after long-term follow-up."